Apyx Medical Corp. Hits New 52-Week High of $3.22

Apyx Medical Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 3.22 on October 13, 2025. This achievement marks a remarkable 87.5% increase in the stock's performance over the past year, significantly outpacing the S&P 500's growth of 13.36% during the same period.
With a market capitalization of USD 78 million, Apyx Medical Corp. operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reflect its current standing, with a debt-to-equity ratio of 0.75, indicating a moderate level of leverage. However, it is important to note that the company is currently loss-making, as evidenced by its negative return on equity of -238.43%.

The stock's journey from a 52-week low of USD 0.76 to its recent high underscores the volatility and potential within the microcap segment of the market. As Apyx Medical Corp. continues to navigate the complexities of the biotechnology landscape, its recent performance highlights the dynamic nature of the industry.